SALT
LAKE CITY, Jan. 7, 2025 /PRNewswire/ --
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or
"Co-Dx"), a molecular diagnostics company with a unique, patented
platform for the development of molecular diagnostic tests,
announced today that it will be participating in Nasdaq's Live from
MarketSite broadcast at the Silicon Slopes Summit 2025 on
January 14, 2025.
Live from MarketSite is Nasdaq's flagship broadcast opportunity,
showcasing innovative leaders and disruptive companies in their
fields. The interview with Co-Dx CEO Dwight
Egan is expected to include a discussion about the upcoming
Co-Dx PCR platform* and its pipeline of tests for COVID-19,
tuberculosis, HPV, and an upper respiratory multiplex panel, as
well as how Co-Diagnostics is positioned to address possible future
health crises arising from infectious diseases such as human
metapneumovirus (HMPV), H5N1, or avian flu, and mpox, formerly
monkeypox.
The Company's existing Co-Dx™ Logix Smart® ABC (Influenza A/B
& SARS-CoV-2) Test already detects all known circulating
strains of H5N1 and is available for purchase by qualified
centralized laboratories as a Research Use Only (RUO)** assay
within the United States, and as
an in vitro diagnostic (IVD) in regions that accept CE markings as
valid regulatory clearance. Co-Diagnostics has also completed the
principal design work and in silico analysis of an H5N1-specific
target, which could be used as a standalone test or even added to
the existing ABC test as needed.
Previously, the Company announced that the results of an
analysis of the Co-Dx™ Logix Smart® Mpox (2-Gene) RUO test showed
that the test should retain full reactivity against mpox strains
circulating over the last year, including clade 1b, and Co-Diagnostics is prepared to launch an
updated 3-gene version of this test, based on the needs of affected
regions.
A post-holiday surge of COVID-19 has shown that the virus
continues to be an unpredictable but persistent threat in
the United States, as some experts
warn that the pandemic is still ongoing and that COVID-19 remains
dangerous.
Once available, the broadcast may be found on Nasdaq's Live from
MarketSite webpage, as well as via the Company's social media
platforms.
*The Co-Dx PCR platform (including the Co-Dx PCR Home™, Co-Dx
PCR Pro™, mobile app, and all associated tests and software) is
subject to review by the FDA and/or other regulatory bodies and is
not available for sale. The Co-Dx PCR Pro instrument and Co-Dx
COVID-19 Test are currently under review by the FDA.
**Co-Dx Logix Smart RUO tests are for research use only and
not for use in diagnostic procedures.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets
state-of-the-art diagnostics technologies. The Company's
technologies are utilized for tests that are designed using the
detection and/or analysis of nucleic acid molecules (DNA or RNA).
The Company also uses its proprietary technology to design specific
tests for its Co-Dx PCR at-home and point-of-care platform and to
locate genetic markers for use in applications other than
infectious disease.
Forward-Looking Statements:
This press release
contains forward-looking statements. Forward-looking statements can
be identified by words such as "believes," "expects," "estimates,"
"intends," "may," "plans," "will" and similar expressions, or the
negative of these words. Forward-looking statements include
statements made with respect to our Co-Dx PCR platform
and its pipeline of tests for COVID-19, tuberculosis, HPV,
and an upper respiratory multiplex panel. Such forward-looking
statements are based on facts and conditions as they exist at the
time such statements are made and predictions as to future facts
and conditions. Forward-looking statements are subject to inherent
uncertainties, risks and changes in circumstances. Actual results
may differ materially from those contemplated or anticipated by
such forward-looking statements. Readers of this press release are
cautioned not to place undue reliance on any forward-looking
statements. There can be no assurance that any of the anticipated
results will occur on a timely basis or at all due to certain risks
and uncertainties, a discussion of which can be found in our Risk
Factors disclosure in our Annual Report on Form 10-K, filed with
the Securities and Exchange Commission (SEC) on March 14, 2024, and in our other filings with the
SEC. The Company does not undertake any obligation to update any
forward-looking statement relating to matters discussed in this
press release, except as may be required by applicable securities
laws.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-participate-at-the-nasdaq-live-from-marketsite-broadcast-at-silicon-slopes-2025-302344233.html
SOURCE Co-Diagnostics
